Clinical Trials Logo

Hematuria clinical trials

View clinical trials related to Hematuria.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02718027 Terminated - Clinical trials for Nephritis, Hereditary

Biomarker for Alport Syndrome (BioAlport)

BioAlport
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

NCT ID: NCT02350543 Terminated - Clinical trials for Urinary Bladder Neoplasms

Peri-operative Aspirin Continuation Versus Discontinuation

Start date: February 2015
Phase: Phase 4
Study type: Interventional

This study evaluates the continuation (non-discontinuation) of Aspirin during TURBT. Half of participants will continue their usual low-dose Aspirin regimen during TURBT and throughout the perioperative period, while the other half will discontinue Aspirin use ten days prior to surgery (standard recommendation) and restart therapy two weeks post-discharge.

NCT ID: NCT02213757 Terminated - Clinical trials for Microscopic Hematuria

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

EVER
Start date: August 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if vaginal estrogen use is associated with resolution of blood in the urine (microscopic hematuria) in postmenopausal women. The hypothesis is that postmenopausal women with blood in the urine (microscopic hematuria) will have higher rates of resolution of hematuria after treatment course with vaginal conjugated equine estrogen cream compared to placebo cream

NCT ID: NCT01600443 Terminated - Hematuria Clinical Trials

Comparison of Microtrauma in Urethra After Usage of Different Catheters

Start date: April 2012
Phase: N/A
Study type: Interventional

The study is undertaken to investigate if the urethral microtrauma, caused by intermittent catheterization, differs between three hydrophilic catheters for intermittent catheterization, LoFric; SpeediCath (SC) and SpeediCath Compact Male (SCCM). The study is a prospective, randomised, cross-over, single-centre study. Each subject will be randomized to use three different catheter types. Three catheterizations will be performed with each catheter type during one day, with at least two hours between each catheterization. The washout period between catheter switch will be at least one week. The primary objective is to evaluate urethral microtrauma for three hydrophilic catheters with regards to hematuria after intermittent catheterization. The secondary objectives are to evaluate urethral microtrauma for three hydrophilic catheters with regards to pyuria and subjective evaluation after intermittent catheterization. The safety of the three catheters will be evaluated in terms of adverse advents, non-serious and serious, rated for causality. The hypothesis that level of hematuria is equal after using different catheters will be tested using Wilcoxon signed rank test. The hypothesis will be rejected if the p-value is less than 5%.

NCT ID: NCT00600691 Terminated - Hematuria Clinical Trials

The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of our study is primarily to evaluate the effects of 5mg finasteride on hematuria and hematospermia commonly associated with prostate biopsies. We hypothesize that 5mg of finasteride daily for two weeks preceding TRUS prostate biopsy and one week following will reduce hematuria and hematospermia commonly seen as complications following prostate biopsy. We also hypothesize that reducing complications will decrease concern among subjects and make for a more tolerable overall procedure than compared with subjects treated with placebo.